ADGRF1and ADGRF5, also named GPR110 and GRP116, are G-protein-coupled receptors acting as important regulators in the progression and development of several human inflammatory diseases including IBD, hepatocellular carcinoma, lung cancer, gastric cancer, prostatic cancer, glioma, and colorectal cancer [45]. Here, ADGRF5 is linked to lung carcinoma.